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Executive summary
Clinical trials are crucial in determining the effectiveness of treatments and directly affect
clinical and policy decisions. These decisions are undermined if the data are problematic
due to data fabrication or other errors. Researchers have worked on developing statistical
methods to detect problematic data. This project aims to develop new methods and apply
them to results reported in the ClinicalTrials.gov database. Using both established and and
the newly developed statistical methods we will investigate the prevalence of problematic
data, trends of problematic data over time, and whether the prevalence of problematic data
is predicted by trial characteristics such as funding type.
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Background
Clinical  trials  are  crucial  in  determining  the  effectiveness  of  medical  interventions  and
directly affect the clinical and policy decisions made by medical doctors and governmental
institutions,  respectively.  If  the  clinical  trial  data  are  problematic,  these  decisions  are
undermined.  A  salient  example  is  the  case  where  beta-blockers  were  prescribed  to
decrease perioperative mortality in cardiac patients, based on what later appeared to be
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problematic data (Commissie Vervolgonderzoek 2012). A subsequent meta-analysis
indicated  beta-blockers  actually  increased  perioperative  mortality  if  the  results  of  the
problematic studies were excluded (Bouri et al. 2014). As a result, patients were exposed
to increased risk instead of decreased risk; had the problematic data not been detected,
they might still have been exposed to increased risk today.
As a result, some researchers have worked on developing statistical methods to detect
problematic data, but this remains a niche field despite the large scientific and societal
benefits of improving these methods. For clinical trials conducted across different locations,
central  statistical  monitoring  can  be  applied  to  detect  aberrant  data  by  comparing  the
summary  results  from  different  collection  sites  (Timmermans  et  al.  2015).  Such  a
monitoring tool is useful because fully verifying the raw data for all locations is practically
infeasible (George and Buyse 2015). Others have developed a posteriori methods, which
apply summary results or raw data to detect problematic data (reviewed in Buyse et al.
1999). For example, 168 trials by Fuji were analyzed based on published summary results,
which indicated that these trials were problematic (Carlisle 2012, Carlisle et al. 2015) and
subsequently resulted in more than 100 retractions.
Problematic data can arise from data fabrication, but can also be the result of erroneous
procedures or data handling. For instance, imagine a randomized clinical trial that shows
severely different baseline measures for two randomized groups. Since these groups are
expected  to  be  statistically  similar,  if  severe  differences  do  occur,  this  can  indicate
something went wrong in the randomization procedure, measurements were improper for
one condition, or data were fabricated (Al-Marzouki et al. 2005).
It remains unclear how prevalent problematic data is throughout the different sciences and
how  the  prevalence  has  developed  throughout  the  years.  Approximately  2%  of  all
researchers admit to having fabricated data, the most egregious form of problematic data,
at least once (Fanelli 2009). Since the 2% estimate is based on self-reports, it is plausible
that it underestimates the true extent of the problem due to response bias. Anecdotally, the
Journal of Cell Biology found that image manipulation, another form of problematic data,
was present in 1% of their accepted manuscripts (Journal of Cell Biology 2015).
With  many  high-exposure  cases  of  problematic  data  throughout  recent  years  and  in
different  scientific  fields  (e.g.,  the  Stapel  case  in  psychology,  the  Fuji  case  in
anesthesiology, the Poldermans case in medicine), it might appear that more problematic
data are published now than a decade ago. However, systematic data on how prevalent
problematic data are and how the prevalence has developed over time are largely absent.
Extending the set  of  statistical  methods available to investigate problematic data helps
increase its detection; systematic application of these methods would provide a prevalence
estimate of problematic data.
Systematic  application  of  statistical  methods  to  detect  problematic  data  and  testing
hypotheses of its prevalence could be done within the ClinicalTrials.gov (CT) database,
which includes over 100,000 completed trials with summary results for more than 15,000
clinical  trials.  The CT database,  where  information  on  clinical  trials  are  available  from
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beginning to completion, allows for a substantial amount of meta-research and includes
data that are reported in a standardized format. Such meta-research can range from meta-
analyses  to  the  adherence  of  preregistration  protocols  in  publications  (i.e.,  outcome
reporting bias). Since, as noted above, an estimated 2% of researchers have admitted to
fabricating data at least once, some of these results can be expected (in part) to be based
on problematic data. Research related to the ClinicalTrials.gov database has amassed 138
research publications in Web of Science since its launch in 2008 (as of October 5, 2015),
but none of these publications explicitly inspected potentially problematic data.
One category of studies available within the CT database are large, multi-location trials that
contain aggregated results based on data collected at multiple locations. As such, if there
are  many  research  locations,  problematic  data  by  one  location  might  be  masked  by
aggregating and consequently remain undetected. Nonetheless, if there are more research
locations, the aggregate data at baseline across randomized groups contains less standard
error. Thus, problematic data with influential (i.e., extreme) outlying values, which severely
distort  the  mean  would  also be  more  readily  detected.  Whether  problematic  data  is
detected is therefore highly dependent on how the data is problematic (e.g., missing values
coded as 999 are included in the analysis for a question ranging from 1-10), a question the
CT database cannot answer and this project therefore does not aim to answer.
The  CT  database  also  contains  other  categories  and  this  project  investigates  the
prevalence  of  problematic  data  for  all  categories  at  the  study  level.  These  categories
include interventional studies and observational studies, including multi-location and single
location studies. The proposed project investigates all categories available and will provide
a  prevalence  estimate  for  all  categories  together,  and  per  category  separately.  The
prevalence within different categories of clinical trials can be directly compared, which can
serve as an indicator for further research.
The prevalence estimates will also be regressed onto trial characteristics, in order to see
whether problematic data is more prevalent for studies that contain certain characteristics.
For example, the hypothesis that industry-funded research is more frequently problematic
than publicly  funded research  can be  directly  tested  by  estimating  whether  there  is  a
difference between the prevalence estimates for industry- and publicly funded research.
Other  trial  characteristics  will  be  mapped  during  the  data  collection  and  flagged  if  of
interest.
Objectives
1. What new statistical methods can be developed to detect problematic data based
on summary results alone (e.g., means, standard deviations, demographics, test
results)?
2. Based on the developed methods, what is the estimated prevalence of potentially
problematic data in the ClinicalTrials.gov database?
3. Based  on  the  developed  methods,  do  the  prevalence  estimates  of  potentially
problematic data in the ClinicalTrials.gov database show a change over time?
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4. Based on the developed methods, are prevalence estimates of potentially
problematic  data  in  the  ClinicalTrials.gov  database  predicted  by  study
characteristics (e.g., funding type)?
Methodology
Clinical  trials  aim  to  make  inferences  about  the  effectiveness  of  a  treatment  in  the
population by taking a sample of that population and clinical trials that do not adhere to the
principles of sampling theory can be said to be problematic. For example, earlier research
highlighted that  researchers are often quite bad in  fabricating data that  look genuinely
stochastic  (Mosimann  et  al.  2002,  Mosimann  et  al.  1995).  Moreover,  if  a  randomized
experimental design includes an honest mistake, for instance assigning all females to the
control group, stochasticity does not fully apply anymore.
As a consequence, the principle of stochasticity can be applied to help detect potentially
problematic data. Some previous methods have been developed that apply this tenet to
detect  problematic  data.  For  example,  the  Simonsohn  method  (Simonsohn  2013)
examines the “variance of variances.” That is, how much the observed variances differ
across  conditions  and  whether  this  is  a  reasonable  amount  given  natural  sampling
fluctuations.  If  the  results  are  highly  unlikely  under  sampling  theory  (e.g.,  10 ),  this
indicates  that  something  might  have  gone  wrong  in  the  data  collection,  for  whatever
reason.
A limited set of methods are currently available to investigate the stochasticity of summary
results—methods this project aims to extend. With an extension of these methods, the
possibility to detect problematic data based on only summary results could increase. These
methods would be tested in simulation studies for their validity before applying them to the
CT  data  themselves.  For  example,  the  uniformity  of  nonsignificant  results  can  be
inspected, or the size of effects found in the clinical trials. Such methods can be based on
previous  misconduct  investigations  and  based  on  theoretical  expectations  of  the  data
under sampling theory. For instance, the Fuji case in anesthesiology (Carlisle 2012) used
statistical tools to indicate that results were too good to be true. Other cases in different
fields also applied statistical tools to detect problematic data, such as the Baltimore case in
biology (Research Integrity Adjudications Panel 1996), the Stapel case (Levelt Committee
et al. 2012), the Smeesters case, and the Sanna case in psychology (Simonsohn 2013).
Considering that methods are developed within the project, the exact methodology is hard
to  outline  a  priori.  The  stochastic tenet  will  serve  as  the  main  driver  to  develop  the
methods. The data from the CT database will be extracted and structured prior to the start
of the project.
An example of such a method is a -test for randomized trials, which tests whether a set
of  baseline  demographics  data  are  statistically  equal  across  groups  after  taking  into
account that different measures have different expected values. The CT database includes
baseline demographics for almost all studies. For each baseline demographic an expected
value  (i.e.,  the  mean  of  the  randomized  groups)  and  a  -value  can  be  computed.
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Repeating this for all reported baseline measures, an overall -test for potentially
problematic data in the baseline is computed as 
where  M  is  the  number  of  measures  and  K  is  the  number  of  groups  available.  The
expected-  and  observed  values  should  not  deviate  substantially  from  each  other  in
randomized  trials  at  the  baseline  measurement,  but  could  deviate  from  each  other  if
something problematic occurred. Because this measure looks at all baseline demographics
simultaneously, the probability of a positive result due to sample fluctuations (i.e., false
positive) decreases.
Significance
Improving the detection of potentially problematic data has two important outcomes: (i)
better methods to detect problems before- and after publication of the results and (ii) a new
way of  estimating  the  prevalence  of  problematic  data,  moving  away from biased self-
reports.  Additionally,  the statistical  detection tools would be of  interest  to the Office of
Research Integrity in the U.S., the Dutch National Board for Research Integrity (LOWI),
academic  editors,  peer-reviewers,  or  (potential)  whistleblowers,  as  part  of  investigating
suspected  papers.  These  detection  tools  might  also  serve  as  a  deterrent  for  data
fabrication by improving its detection. Moreover, these statistical methods would not be
limited to clinical trials, but could also be applied in other fields (e.g., psychology).
Professionally, the project would allow me to learn from one of the few experts in this niche
field and discuss the intricacies of researching problematic data. Besides advancing the
methods themselves, the limitations of these methods and their ethical implications will
provide sufficient discussion during the visit,  promoting my academic development with
respect  to the implications of  the methods and their  findings.  As such, this visit  would
provide a bridge between my local supervisors (Jelte M. Wicherts and Marcel A.L.M. van
Assen),  experts  located  in  the  Netherlands,  and  researchers  in  the  U.S.,  potentially
providing further international collaborations in the future.
Evaluation and dissemination
Upon submission, this proposal will be published in the the Research Ideas and Outcomes
(RIO) journal for public evaluation. The research project will be publicly documented with
the Open Science Framework and GitHub, allowing for direct reproduction of all analyses
and results.  This  allows for  rapid  dissemination and participation of  fellow researchers
during the project. The Open Science Framework and GitHub apply version control, which
is a track changes for files (Ram 2013 ), providing a revision history of all changes applied
and  improves  (chronological)  documenation  of  the  research  process.  The statistical
methods used during the project will be implemented into the `ddfab` package in R, which
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is under development by the applicant and will be made freely available. The results of the
project itself will be checked by another researcher (i.e., co-piloted) and written up in a
manuscript that will be submitted to a peer-reviewed Open Access journal. This manuscript
will be shared as a preprint for public feedback. All research output will be made available
with nonrestrictive Creative Commons licenses, with an explicit preference for the public
domain (i.e., CC-0) and otherwise only requiring attribution (i.e., CC-BY). Such
nonrestrictive licenses allow for maximum re-use and impact of the research.
Justification for residence in the United States for the proposed
project
Research  on  detecting  potentially  problematic  data  is  a  niche  field;  the  number  of
researchers that also have experience with these methods within the medical sciences is
even more limited. Stephen L. George (SLG) combines knowledge of statistics in general,
clinical trials, and the application of statistics to detect potentially problematic data due to
for example research misconduct. He has extensive knowledge of these methods (Buyse
et al. 1999) and how these can be used to provide estimates of incidence or prevalence of
research misconduct  (George 2015,  George and Buyse 2015).  Moreover,  his  thorough
case  knowledge  and  mathematical  background  will  help  in  developing  new  statistical
methods to detect problematic data. Hence, the current project would thoroughly benefit
from discussion and supervision by SLG.
Duration
The proposed project  lasts  six  months;  Table  1 includes a  preliminary  specification of
activities prior to- and during the visit. The proposed project entails analyzing data retrieved
from the ClinicalTrials.gov database; the data will be extracted in the two months prior to
visiting  the  U.S.  as  preparation.  Upon arrival,  the  applicant  outlines  the  types of  data
available  in  the  database (including  recalculated  results)  and,  together  with  the  onsite
supervisor  (SLG),  inspects  which  available  methods  might  be  useful  to  apply  to  this
database to detect problematic data. Moreover, upon outlining the types of data available,
the applicant and SLG also discuss potential avenues for new methods. The application of
these methods to the ClinicalTrials.gov data is postponed until the statistical properties of
these  methods  are  further  investigated.  During  this  process,  the  methods  are  also
incorporated as functions in the R statistical  environment (R Core Team 2015),  if  they
appear valuable. Subsequently, the remaining methods are applied to the ClinicalTrials.gov
database to estimate the prevalence of potentially problematic data.
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 2017 (month)
 Preparation Visit U.S.
What 1 2 3 4 5 6 7 8
Data collection from ClinicalTrials.gov ✓ ✓       
Recalculate test statistic information  ✓ ✓      
Review applicability available methods   ✓      
Develop new method(s)   ✓ ✓ ✓ ✓   
Investigate statistical properties of new method(s)   ✓ ✓ ✓ ✓   
Implement methods in R   ✓ ✓ ✓ ✓   
Apply methods to data collected from ClinicalTrials.gov      ✓ ✓  
Write paper on project ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
English proficiency
The applicant is a proficient English speaker, reader, and writer as a result of his extended
exposure to the English language from an early age. His secondary education was in a
bilingual fashion (English/Dutch) and he followed an English master programme. These
educational  aspects  helped increase the technical  aspects  of  his  English,  whereas his
vocabulary was built by reading books written or translated by native English speakers.
Funding program
This  grant  proposal  was  written  for  the  Dutch  Fulbright  application   (academic  year
2016-2017) due on December 1, 2015. This is a direct copy of the  submitted research
proposal.
Author contributions
CHJH conceptualized the proposal, CHJH drafted the proposal, CHJH and SLG revised
the proposal.
Table 1. 
Preliminary planning of the proposed project, specified per month, including preparatory work prior
to visiting.
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